Competition for covid-19 drugs that really work
[ad_1]
But treatment options against antibodies have their drawbacks. It is expensive and should be given via infusion or injection. This makes them a good choice in many low-income countries. And they won’t do well against other types of travel. Instead, on June 25 the FDA suspended the distribution of Lilly’s stores across the country due to the number of two complications that appear to be unresponsive to the drug.
When it comes to antiretroviral drugs, which interfere with the effectiveness of the virus, there are a few options. Remdesivir is the only drug that is approved to treat covid-19, mainly because it was one of the few that was tested for immunity after the plague, so it started. But how it works is still an open question. Some studies have found that to shorten the duration of the disease, while others say it has no side effects. The World Health Organization recommends no use for this purpose.
Deceptive methods
The growth of antiviral has lagged behind for a variety of reasons. Until covid-19, companies did not have much money to manufacture the drug. The existing antivirals fight only 10 viruses, and half of them cure HIV. Infectious diseases require more long-term treatment to make more money. “If there is no well-known pharmaceutical market, then they are not going to sell these drugs,” said John Bamforth, director of READDI, public relations at the University of North Carolina at Chapel Hill.
There are also a number of scientific problems. By preventing recurrence, the drug binds to the protein or essential vitamins of the virus and inhibits its function without damaging the recipient cell. But unlike bacteria, viruses depend on the machinery in the cells where they replicate themselves, which is why they contain so little protein. And even when researchers meet with a working group, its effectiveness is short-lived because viruses change continuously.
Some researchers, including those on READDI, are using drugs that fight against the need for viral proteins. Most pesticides use only one virus. The hope is that the drug will be able to cope with whole families. They may also be less likely to drive resistance.
But new therapies take longer to develop. That is why the fastest way to get medicine on the shelves is to recycle prescription drugs. They have been tested for safety, and there are few attempts to re-use existing drugs. DNDi is testing a variety of variables in the clinical trials called ANTI-COV. Recent research is looking at anti-parasite nitazoxanide drugs in combination with steroid injections. “The consensus available is that you may need antiviral or infectious agents using a variety of methods, including some form of anti-inflammatory,” says Cohen.
[ad_2]
Source link